Genetic Predictors of Long-Term Response to Growth Hormone (GH) Therapy in Children With GH Deficiency and Turner Syndrome: The Influence of a SOCS2 Polymorphism
Carregando...
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
ENDOCRINE SOC
Autores
COSTALONGA, Everlayny F.
MALAQUIAS, Alexsandra C.
GUERRA-JUNIOR, Gil
ANTONINI, Sonir R. R.
Citação
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.99, n.9, p.E1808-E1813, 2014
Resumo
Background: There is great interindividual variability in the response to GH therapy. Ascertaining genetic factors can improve the accuracy of growth response predictions. Suppressor of cytokine signaling (SOCS)-2 is an intracellular negative regulator of GH receptor (GHR) signaling. Objective: The objective of the study was to assess the influence of a SOCS2 polymorphism (rs3782415) and its interactive effect with GHR exon 3 and -202 A/C IGFBP3 (rs2854744) polymorphisms on adult height of patients treated with recombinant human GH (rhGH). Design and Patients: Genotypes were correlated with adult height data of 65 Turner syndrome (TS) and 47 GH deficiency (GHD) patients treated with rhGH, by multiple linear regressions. Generalized multifactor dimensionality reduction was used to evaluate gene-gene interactions. Results: Baseline clinical data were indistinguishable among patients with different genotypes. Adult height SD scores of patients with at least one SOCS2 single-nucleotide polymorphism rs3782415-C were 0.7 higher than those homozygous for the T allele (P < .001). SOCS2 (P < .003), GHR-exon 3 (P = .016) and -202 A/C IGFBP3 (P = .013) polymorphisms, together with clinical factors accounted for 58% of the variability in adult height and 82% of the total height SD score gain. Patients harboring any two negative genotypes in these three different loci (homozygosity for SOCS2 T allele; the GHR exon 3 full-length allele and/or the -202C-IGFBP3 allele) were more likely to achieve an adult height at the lower quartile (odds ratio of 13.3; 95% confidence interval of 3.2-54.2, P = .0001). Conclusion: The SOCS2 polymorphism (rs3782415) has an influence on the adult height of children with TS and GHD after long-term rhGH therapy. Polymorphisms located in GHR, IGFBP3, and SOCS2 loci have an influence on the growth outcomes of TS and GHD patients treated with rhGH. The use of these genetic markers could identify among rhGH-treated patients those who are genetically predisposed to have less favorable outcomes.
Palavras-chave
Referências
- Braz AF, 2012, J CLIN ENDOCR METAB, V97, pE671, DOI 10.1210/jc.2011-2521
- Chan YL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002439
- Clayton P, 2013, EUR J ENDOCRINOL, V169, P277, DOI 10.1530/EJE-13-0069
- Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
- Flores-Morales A, 2006, MOL ENDOCRINOL, V20, P241, DOI 10.1210/me.2005-0170
- Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
- Greenhalgh CJ, 2005, J CLIN INVEST, V115, P397, DOI 10.1172/JCI200522710
- Gudbjartsson DF, 2008, NAT GENET, V40, P609, DOI 10.1038/ng.122
- Lango AH, 2010, NATURE, V467, P832, DOI 10.1038/NATURE09410
- Lanktree MB, 2011, AM J HUM GENET, V88, P6, DOI 10.1016/j.ajhg.2010.11.007
- Lou XY, 2007, AM J HUM GENET, V80, P1125, DOI 10.1086/518312
- Ranke MB, 2003, J CLIN ENDOCR METAB, V88, P125, DOI 10.1210/jc.2002-020867
- Ranke MB, 2005, J CLIN ENDOCR METAB, V90, P1966, DOI 10.1210/jc.2004-1051
- Ranke MB, 2000, J CLIN ENDOCR METAB, V85, P4212, DOI 10.1210/jc.85.11.4212
- Renehan AG, 2012, AM J EPIDEMIOL, V175, P867, DOI 10.1093/aje/kwr408
- Stevens A, 2014, PHARMACOGENOMICS J, V14, P54, DOI 10.1038/tpj.2013.14
- Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425
- Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121